/ /

Lynda Charters
New glaucoma drug significantly lowers IOP
A new fixed-dose combination medication (Simbrinza, Alcon Laboratories) for the reduction of elevated IOP combines brinzolamide 1%, a carbonic anhydrase inhibitor, and brimonidine tartrate 0.2%, an alpha 2 adrenergic receptor agonist, in one multidose bottle. The drug is also the only available, fixed-dose combination therapy for glaucoma without a beta blocker in the United States, according to the manufacturer.
Meaningful pharmacologic pupil dilation possible after death
Pupils can be pharmacologically dilated after death, according to the results of a recent study. The study examined pupillary dilation of postmortem eye bank eyes, which may facilitate postmortem examination and screening through modalities such as fundus photography and fundus optical coherence tomography.
Slow-release therapy for AMD, DME on horizon
Slow release of surrogate proteins over several months has been demonstrated in vitro from injectable hydrogel depots. This technology could help create long-term, sustained-release treatments of anti-vascular endothelial growth factor drugs.
Corneal collagen crosslinking indications expanding
Indications for riboflavin ultraviolet crosslinking have been expanding. As such, the technology may be useful for more than just treating keratoconus—by filling a gap in which other surface therapies sometimes cannot be effective.
Treating recurrent pediatric retinal detachment after initial repair
Recurrent retinal detachments in children can develop months to years after the initial corrective surgery, making careful monitoring of patients imperative to identifying late re-detachments.
Corneal shield improves vision after PRK, LASIK
The immediate postoperative period after PRK and LASIK can be difficult for patients because of refractive variations, surface irregularities, and poor optical clarity. However, a novel eye shield (Nexis Vision Corneal Shield, Nexis Vision) appears to help patients who have undergone PRK and LASIK by providing rapid visual and functional recovery.
Secondary IOL implantation safe in pediatric patients
Secondary IOL implantation is widely accepted, especially in aphakic patients who have become contact lens intolerant or noncompliant. A number of studies on the topic, mostly from Western countries, have had small sample sizes, and the safety and efficacy of the procedure have not been well studied.
AREDS gets another look
Removing beta-carotene, adding lutein/zeaxanthin show clear patient benefits
Gene therapy of choroideremia on the horizon
Ian MacDonald, MSc, MD, talked about the future of gene therapy trials in choroideremia, a single-gene disorder that primarily affects the eye.
Retinectomy: Contribution to vitreoretinal surgery
The frequency with which retinectomy is performed has increased dramatically. Major management factors involve instruments, lensectomy and scleral buckling, the anterior retina, and complications.


View Results